Janus Henderson Horizon Biotechnology Fund has a track record back to 2018. The management company, Janus Henderson Investors, was formed in 2017 through the merger of Janus Capital and Henderson Global Investors. Its headquarters are in London, with a large investment hub in Denver. The company has been privately owned since 30 June 2026 by an investor group led by Trian Fund Management and General Catalyst.
Investment philosophy
The fund aims for long-term capital growth and outperformance of 2% per year, before charges, over any five-year period against the NASDAQ Biotechnology Total Return Index.
The managers
The fund is managed by the Janus Henderson Health Care Team in Denver, led by Andy Acker. He has led the firm's healthcare research since 2007 and joined Janus in 1999. Agustin Mohedas joined the firm in 2019 after working as an analyst at the hedge fund RA Capital, and Daniel Lyons has been a portfolio manager since 2018 and an analyst since 2000. All of the managers combine the roles of analyst and portfolio manager. Lyons holds a PhD in immunology from Stanford, Mohedas holds a Harvard-MIT PhD in medical engineering, and Acker holds an MBA from Harvard Business School.
The portfolio
The portfolio holds many companies, but with a noticeable top weight and a few core positions that recur over time, including Revolution Medicines, Argenx, Vertex Pharmaceuticals, Gilead Sciences and Praxis Precision Medicines. The centre of gravity is in mid-sized companies, with spread into both smaller and larger ones.
Fund data is taken from the managers’ own reports, otherwise computed from NAV history and, as a last resort, taken from distributor listings. Not official figures; verify with the fund provider before investing.